Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

NCT00983060 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C Genotype-1 Relapse

Interventions

DRUG: NIM811
DRUG: Placebo BID + SOC

Sponsor

Novartis Pharmaceuticals